Trial Profile
A Real-World Cross-Sectional Study to compare physician-evaluated patient adherence in patients treated with Delayed-Release Dimethyl Fumarate compared to compared to those receiving Injectable Platform Therapies
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2018
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Glatiramer acetate; Interferon beta-1a; Interferon beta-1b; Peginterferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 02 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research